BioSpace News Archive

The live conference call on Tuesday, November 5, 2019, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 2980632.

Successful healthcare entrepreneur and industry executive uniquely positioned to help activate growth and scale

The poster presentations will highlight preclinical data from three of Aptinyx’s clinical-stage product candidates that are in development for chronic pain, PTSD, and cognitive impairment.

The company recently launched an inter-connected platform with select partners that represent the cutting-edge of wound care devices.

He is now a board member of the combined Clockspring-NRI corporation.

Experienced Industry Executives to Lead Clinical Research and Regulatory Affairs with the Appointments of James Wooldridge, MD, as Chief Medical Officer and Steven Hamburger, PhD, as Vice President of Regulatory Affairs

BioIQ, a healthcare engagement and gap closure company that is redefining the way payers, employers and consumers navigate and connect with the U.S. healthcare system, has named Ashley L. Reynolds, PhD, RN, ACSM-HFS as its new chief experience officer.

Sun Ophthalmics, the branded ophthalmic division of Sun Pharmaceuticals Industries Inc, USA, which is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), will present seven poster presentations at the joint annual meeting of the American Academy of Optometry (AAOPT) and the 3rd World Congress of Optometry (WCO) in Orlando, Fla. (Oct. 23-27)

HTG Molecular Diagnostics, Inc. announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory at the end of October 2019.

Ziopharm Oncology, Inc., announced that Chris Bowden, M.D., an oncology drug development executive with more than 20 years leadership experience spanning pre-clinical development through commercialization, including the approval of several cancer medicines, has been appointed to the Company’s Board of Directors.